Traws Pharma, Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Filed herewith.
Furnished herewith.
† The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
| Date: April 15, 2026 | | |
|---|---|---|
| | Traws Pharma, Inc. | |
| | | |
| | By: | /s/ Iain Dukes, D. Phil |
| | | Iain Dukes, D. PhilChief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ Iain Dukes, D. Phil | | Chief Executive Officer and Director(Principal Executive Officer) | | April 15, 2026 |
| Iain Dukes, D. Phil | | | | |
| | | | | |
| /s/ Charles Parker | | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | April 15, 2026 |
| Charles Parker | | | | |
| | | | | |
| /s/ Jack E. Stover | | Executive Chairman, Board of Directors | | April 15, 2026 |
| Jack E. Stover | | | | |
| | | | | |
| /s/ Nikolay Savchuk, PH.D. | | Director | | April 15, 2026 |
| Nikolay Savchuk, Ph.D. | | | | |
| | | | | |
| /s/ Trafford Clarke, PH.D. | | Director | | April 15, 2026 |
| Trafford Clarke, Ph.D. | | | | |
| | | | | |
| /s/ Mary Teresa Shoemaker | | Director | | April 15, 2026 |
| Mary Teresa Shoemaker | | | | |
| | | | | |
| /s/ John Leaman, MD | | Director | | April 15, 2026 |
| John Leaman, MD | | | | |
| | | | | |
| /s/ Werner Cautreels, Ph.D. | | Director | | April 15, 2026 |
| Werner Cautreels, Ph.D. | | | | |
| | | | | |
| | | | | |
| | | | |
Index to Consolidated Financial Statements
| | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (KPMG LLP, Philadelphia, PA, PCAOB ID: 185) | F-2 |
| | |
| Consolidated Balance Sheets, December 31, 2025 and 2024 | F-4 |
| | |
| Consolidated Statements of Operations, Years ended December 31, 2025 and 2024 | F-5 |
| | |
| Consolidated Statements of Comprehensive Income (Loss), Years ended December 31, 2025 and 2024 | F-6 |
| | |
| Consolidated Statements of Stockholders’ Equity (Deficit), Years ended December 31, 2025 and 2024 | F-7 |
| | |
| Consolidated Statements of Cash Flows, Years ended December 31, 2025 and 2024 | F-8 |
| | |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.